Comparative evaluation of clinical outcomes of dapagliflozin and empagliflozin in type-2 diabetes mellitus.

Hakan Doğruel Hatice Tülüce Atlım Mustafa Aydemir Nusret Yılmaz Ramazan Sarı

Published in: Irish journal of medical science (2022)

Dapagliflozin and empagliflozin are the drugs to choose for renoprotection in diabetics independent of the use of a RAAS blocker. Even the time to addition of a new anti-diabetic agent is longer in the empagliflozin group, head-to-head comparative trials are needed to asess the potential differences in this regard.

Keyphrases

optic nerve
type diabetes
metabolic syndrome
glycemic control
skeletal muscle
risk assessment
angiotensin ii